Han Biomedical, Inc.

As of June 30, 2026, Han Biomedical, Inc. carries a market capitalization of 649.44M, placing it among publicly traded companies globally. Its enterprise value stands at 485.76M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of June 30, 2026, Han Biomedical, Inc. has 23.12M shares outstanding.

These figures are as of June 30, 2026.

As of June 30, 2026, Han Biomedical, Inc. maintains a current ratio of 5.86, meaning it holds 5.9x the short-term assets needed to cover near-term liabilities.

As of the close on October 22, 2026, Han Biomedical, Inc.'s stock has declined approximately 21.96% over the past 52 weeks. The 50-day moving average sits at 28.25, while the 200-day moving average is 30.00.

As of June 30, 2026, Han Biomedical, Inc. holds 180.03M in cash and equivalents against 16.34M in total debt, resulting in a net debt position of -100.03M. Total book value stands at 258.77M, with working capital of 210.31M providing operational flexibility.

Han Biomedical, Inc.'s most recent stock split took place on August 3, 2026 with a 20:21 split ratio.